Eli Lilly and Company (LLY) Stock Price, News & Analysis

Company Overview

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company renowned for its commitment to research and development of innovative therapies. Founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana, the company has evolved into one of the world’s leading developers of prescription medicines. Its primary business activities encompass discovery, development, manufacturing and commercialization of a broad range of pharmaceutical products targeting critical disease areas.

Lilly’s product portfolio spans several therapeutic categories, including endocrinology, immunology, oncology, neuroscience and cardiovascular health. The company is particularly recognized for its leadership in diabetes care, offering insulin and non-insulin therapies designed to improve patient outcomes. In oncology, Lilly has advanced treatments such as targeted therapies and immuno-oncology agents. Its neuroscience pipeline focuses on conditions like Alzheimer’s disease and migraine, while immunology offerings address autoimmune disorders such as rheumatoid arthritis and psoriasis.

Research and development is a cornerstone of Lilly’s strategy, with significant investments directed toward delivering first-in-class and best-in-class medicines. The company maintains a global network of research centers and collaborates with academic institutions, biotechnology firms and nonprofit organizations to accelerate scientific breakthroughs. In recent years, Lilly has expanded its R&D footprint in the United States, Europe and Asia, reflecting its ambition to bring novel therapies to patients worldwide.

Operating in more than 120 countries, Eli Lilly and Company manages a diverse array of manufacturing facilities, distribution sites and commercial offices to support its global supply chain and ensure product availability. Led by President and CEO David A. Ricks, the company emphasizes corporate responsibility through initiatives in sustainability, integrity and patient access programs. With a history of over 140 years, Lilly continues to focus on addressing unmet medical needs and enhancing health outcomes across the globe.

Key Stats

• Today's Range: $773.00 to $783.55
• 50-Day Range: $713.99 to $899.78
• 52-Week Range: $677.09 to $972.53
• Volume: 1.45 million shs
• Average Volume: 3.66 million shs
• Market Capitalization: $738.85 billion
• P/E Ratio: 63.43
• Dividend Yield: 0.77%
• Price Target: $1,011.61
• Consensus Rating: Moderate Buy

Eli Lilly and Company Stock Analysis - MarketRank™

Eli Lilly and Company scored higher than 100% of companies evaluated by MarketBeat, and ranked 8th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 16 buy ratings, 3 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Eli Lilly and Company has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 32.54%

Earnings Growth

Earnings for Eli Lilly and Company are expected to grow by 32.54% in the coming year, from $23.48 to $31.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eli Lilly and Company is 63.43, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.63.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eli Lilly and Company is 63.43, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.58.

Price to Earnings Growth Ratio

Eli Lilly and Company has a PEG Ratio of 1.14. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Eli Lilly and Company has a P/B Ratio of 51.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.94% of the float of Eli Lilly and Company has been sold short.

Short Interest Ratio / Days to Cover

Eli Lilly and Company has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eli Lilly and Company has recently decreased by 0.12%, indicating that investor sentiment is improving.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Eli Lilly and Company has a dividend yield of 0.77%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Eli Lilly and Company has been increasing its dividend for 11 years.

Dividend Coverage

The dividend payout ratio of Eli Lilly and Company is 48.82%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 19.28% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -2.25

Percentage of Shares Shorted

0.94% of the float of Eli Lilly and Company has been sold short.

Short Interest Ratio / Days to Cover

Eli Lilly and Company has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eli Lilly and Company has recently decreased by 0.12%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.32

News Sentiment

Eli Lilly and Company has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 115 news articles for Eli Lilly and Company this week, compared to 89 articles on an average week.

Search Interest

Only 99 people have searched for LLY on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.

MarketBeat Follows

Only 53 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is a decrease of -41% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eli Lilly and Company insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.13% of the stock of Eli Lilly and Company is held by insiders.

Percentage Held by Institutions

82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LLY Stock Analysis - Frequently Asked Questions

How have LLY shares performed this year?

Eli Lilly and Company's stock was trading at $772.00 on January 1st, 2025. Since then, LLY stock has increased by 1.0% and is now trading at $779.5950.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings data on Thursday, May, 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by $1.30. The company's quarterly revenue was up 45.2% on a year-over-year basis.
Read the conference call transcript.

Is Eli Lilly and Company buying back stock?

Eli Lilly and Company's board initiated a share buyback program on Monday, December 9th 2024, which permits the company to repurchase $15,000,000,000 in shares, according to EventVestor. This means that the company could purchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's management believes its stock is undervalued.

Does Eli Lilly and Company have any subsidiaries?

Eli Lilly and Company subsidiaries include these companies: Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and more.

Who are Eli Lilly and Company's major shareholders?

Eli Lilly and Company's top institutional shareholders include LVM Capital Management Ltd. MI (0.01%), Jacobs & Co. CA, Rowlandmiller & PARTNERS.ADV and Neville Rodie & Shaw Inc.. Insiders that own company stock include Lilly Endowment Inc, Jackson P Tai, Anne E White, Patrik Jonsson, Johna Norton, Alonzo Weems, Donald A Zakrowski and Acquisition Corp Kearny.
View institutional ownership trends.

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Broadcom (AVGO), NVIDIA (NVDA), Meta Platforms (META), BlackRock (BLK), Salesforce (CRM), Chevron (CVX) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/01/2025
• Record date for 6/10 Dividend: 5/16/2025
• Ex-Dividend for 6/10 Dividend: 5/16/2025
• Dividend Payable: 6/10/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:LLY
• CIK: 59478
• Web: www.lilly.com
• Phone: (317) 276-2000
• Fax: 317-276-4878
• Employees: 47,000
• Year Founded: 1876

Price Target and Rating

• Average Stock Price Target: $1,011.61
• High Stock Price Target: $1,190.00
• Low Stock Price Target: $700.00
• Potential Upside/Downside: +29.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): $12.29
• Trailing P/E Ratio: 63.43
• Forward P/E Ratio: 33.20
• P/E Growth: 1.14
• Net Income: $10.59 billion
• Net Margins: 22.67%
• Pretax Margin: 27.75%
• Return on Equity: 85.51%
• Return on Assets: 15.74%

Debt

• Debt-to-Equity Ratio: 2.18
• Current Ratio: 1.37
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: $45.04 billion
• Price / Sales: 16.40
• Cash Flow: $14.22 per share
• Price / Cash Flow: 54.84
• Book Value: $15.03 per share
• Price / Book: 51.87

Miscellaneous

• Outstanding Shares: 947,740,000
• Free Float: 946,504,000
• Market Cap: $738.85 billion
• Optionable: Optionable
• Beta: 0.40